Meloxicam is a new preferential cvclooxygenase-2 (COX-2) inhibitor currently for the treatment of osteoarthritis and rheumatoid arthritis. The current article highlights the potential role of this molecule in treating osteoarthritis. Non-steroidal anti-inflammatory drugs (NSAIDs) are extensively used to reduce inflammation and associated pain in rheumatic diseases and other disorders. During acute, painful exacerbations of rheumatoid arthritis and sciatica and rapid pain is required.
Meloxicam Meloxicam is a novel NSAID which inhibits cvclooxygenase-2 (COX-2) more potently than COX-1 Its pharmacokinetic profile is characterized by a prolonged and almost complete absorption and the drug is >99.5% bound to plasma proteins. Pharmacokinetics Absorption Single oral doses of the drug achieved mean Cmax within 2 hours. Meloxicam administered under fed conditions results in 22% lower mean…
